Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death

• Hlavní autoři: Tarek El-Sewedy (Autor), Afrah Fatthi Salama (Autor), Amro E. Mohamed (Autor), Nashwa M. Elbaioumy (Autor), Ali H. El-Far (Autor), Aisha Nawaf Albalawi (Autor), Alaa Elmetwalli (Autor)
• Médium: Kniha
• Vydáno: BMC, 2023-09-01T00:00:00Z.
• Témata: article
• On-line přístup: Connect to this object online.

Abstract Background Sorafenib (Sor) is the only approved multikinase inhibitor indicated for the treatment of HCC. Previous studies have shown that amygdalin (Amy) possesses anticancer activities against several cancer cell lines; we suggested that these compounds might disrupt AMPK/mTOR and BCL-2....